| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:1326-1329.)
© 2004 American Heart Association, Inc.
Original Articles |
From Divisione IV Clinica Medica (P.P., D.F., F.V.) and Dipartimento di Medicina Sperimentale e Patologia (P.P., L.L., F.V.), Università di Roma "La Sapienza," and Dipartimento di Medicina Interna (V.S.) and Dipartimento di Medicina Sperimentale (A.F., P.R.), Università di Roma Tor Vergata, Rome, Italy.
Correspondence to Francesco Violi, MD, Divisione IV Clinica Medica, Dipartimento di Medicina Sperimentale e Patologia, Università di Roma "La Sapienza," Policlinico Umberto I, 00185, Rome, Italy. E-mail Francesco.Violi{at}uniroma1.it
Received November 21, 2003; de novo received March 18, 2004; revision received May 20, 2004; accepted May 20, 2004.
| Abstract |
|---|
|
|
|---|
Methods and Results CD40L expression was measured in platelets from healthy subjects both with and without the addition of antioxidants or a phospholipase A2 (PLA2) inhibitor and in platelets from 2 patients with an inherited deficiency of gp91phox. Immunoprecipitation analysis was also performed to determine whether normal platelets showed gp91phox expression. Unlike catalase and mannitol, superoxide dismutase inhibited agonist-induced platelet CD40L expression in healthy subjects. Immunoprecipitation analysis also showed that platelets from healthy subjects expressed gp91phox. In 2 male patients with inherited gp91phox deficiency, collagen-, thrombin-, and arachidonic acid-stimulated platelets showed an almost complete absence of superoxide anion (O2) and CD40L expression. Incubation of platelets from healthy subjects with a PLA2 inhibitor almost completely prevented agonist-induced O2 and CD40L expression.
Conclusions These data provide the first evidence that platelet CD40L expression occurs via arachidonic acidmediated gp91phox activation.
Key Words: CD40 ligand NADPH oxidase oxidative stress platelets
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Platelet Isolation From Whole Blood
Blood samples were mixed with 0.13 mol/L sodium citrate (9:1 ratio). Washed platelets and platelet-rich plasma were prepared as previously described.3
Flow Cytometric Analysis
CD40L and CD62P expression on platelet membrane was analyzed with specific fluorescein isothiocyanate conjugated-labeled monoclonal antibodies (Mab). An irrelevant isotype-matched antibody (anti-IgG1) was used as a negative control.
Mab (20 µL) was added to platelets (200 µL, 2x108/mL) previously fixed with 2% paraformaldehyde in PBS (0.1% bovine serum albumin) and incubated for 60 minutes at 4°C. The unbound Mab was removed by addition of 0.1% bovine serum albumin PBS and centrifugation at 500g for 3 minutes (twice). Fluorescence intensity was analyzed on an Epics XL-MCL Cytometer (Coulter Electronics) equipped with an argon laser at 488 nm. For every histogram, 50 000 platelets were counted to evaluate the percentage of positive platelets. Antibody reactivity is reported as mean fluorescence according to this formula: Mean fluorescence of specific antibody minus mean fluorescence of control antibody. Platelets were incubated 10 minutes at 37°C with the antioxidants, AACOCF3 (a PLA2 inhibitor), or control medium before stimulation.
Analysis of Superoxide Anion
Superoxide anion (O2) production was measured by lucigenin (5 µmol/L)3 and expressed as stimulation index (mean level of stimulated platelet luminescence divided by average level of luminescence in unstimulated platelets).
Analysis of sCD40L
After 10 minutes of stimulation with agonists, the reaction was blocked by acidification of the medium with ACD (d-sodium hydrogen citrate, d+glucose, and citric acid), platelet-rich plasma was centrifuged (10 minutes at 360g), and the supernatant was stored at 80°C until use. sCD40L was measured with a commercial immunoassay (Quantikine CD40 Ligand, R&D Systems).
Immunoprecipitation and Western Blotting
The 91phox was immunoprecipitated from platelets (25x109 cells, 55 mg protein/0.5 mL) and polymorphonuclear neutrophils (PMN) (5x106 cells) as positive controls in denaturized condition using a 91phox Ab polyclonal, size separated on SDS-PAGE (12% gel), blotted, and stained with 91phox polyclonal Ab. Negative controls involved a similar procedure using a goat IRR.4
X-Linked Chronic Granulomatous Disease Patient Description
X-linked chronic granulomatous disease (X-CGD), an inherited disorder characterized by the absence or deficiency of phagocyte-NADPH oxidase activity, was diagnosed in 2 male patients (33 and 38 years of age) by demonstrating the absence or manifest deficiency of oxidase activity in stimulated neutrophils.5 X-CGD diagnosis was subsequently confirmed by the mutation analysis of the CYBB gene encoding the gp91 subunit of phagocyte-NADPH oxidase.6 The mutation in patient 1 was identified as a single-base substitution of guanosine to adenosine at residue 252 in exon 3, resulting in a splicing defect. A deletion of thymine 184 in exon 3 was identified for patient 2, resulting in a frame shift.
Platelet Aggregation
Collagen-induced platelet aggregation (Borns method) was measured as previously described.3
Statistical Analysis
Data are reported as mean±SD. Comparison between variables in the in vitro study was analyzed by Students t test for unpaired data; the correlation study between CD40L expression and O2 and H2O2 formation was evaluated by linear correlation analysis, followed by ANOVA.
| Results |
|---|
|
|
|---|
|
To determine the role of arachidonic acid in the interaction between O2 and CD40L, agonist-stimulated platelets from healthy subjects were investigated with or without the addition of AACOCF3. Compared with controls, platelets treated with AACOCF3 showed a significantly lower expression of O2 (79% with collagen and 66% with thrombin; P<0.001; n=10) and CD40L (Figure 1). Conversely, incubation of platelets with aspirin reduced O2 by 17% (P<0.05) with collagen and by 13% (P=NS) with thrombin but did not change CD40L expression (Figure 1); the specific thromboxane receptor inhibitor SQ 29548 did not change either platelet O2 or CD40L (not shown).
To determine whether gp91phox is detectable in human platelets, we performed an in vitro study in platelets from healthy volunteers. Neutrophils were tested as positive controls, and an IRR was tested as a negative control. In this experiment, denaturized conditions were used to prevent interference of gp22phox with gp91phox detection on account of their natural complex form (flavocytochrome b558). Leukocyte contamination in platelet suspension was assessed to be <0.1% (50 PMN per 50 000 platelets per 1 mL). A leukocyte suspension (1x103 PMN/mL diluted to obtain 50 PMN/mL) was immunoprecipitated, showing no gp91phox expression. Immunoprecipitation of the platelet sample allowed us to demonstrate that gp91phox is expressed by human platelets (Figure 2A).
|
The role of gp91phox in CD40L expression was then investigated in 2 patients affected by X-CGD and in male control subjects matched for age. Compared with control subjects, X-CGD patients showed almost complete suppression of CD40L and O2 by collagen- and thrombin- stimulated platelets (Figure 2C and 2D). Similar findings were observed with arachidonic acid, thus suggesting that, in platelets, NADPH oxidase activation and subsequent CD40L expression occur via arachidonic acid pathway (Figure 2C and 2D). In the 2 patients with X-CGD, plasma levels of sCD40L were much lower than those found in healthy subjects and did not increase after platelet stimulation with the agonist (Figure 2B). In patients with X-CGD, collagen (4 µg/mL)-induced platelet aggregation (patient 1: lag phase, 30 seconds; light transmission%, 88; and patient 2: lag phase, 25 seconds; light transmission%, 91%) was comparable to that of healthy subjects (lag phase, 25+5 seconds; light transmission%, 85+9, n=10).
| Discussion |
|---|
|
|
|---|
These findings imply that platelets express gp91phox, an NADPH oxidase subunit that had not been previously detected in platelets. In fact, only the gp22phox, gp47phox, and gp67phox subunits have been found so far.7 In this study, we provide the first evidence that platelets express gp91phox and demonstrate that NADPH oxidase has a central role in generating O2 in platelets, like in phagocytic and nonphagocytic cells.8,9
The intracellular signaling eliciting NADPH oxidase activation by agonist-activated platelets is still unclear. Arachidonic acid has been shown to be an important respiratory burst activator.10
Previous studies have demonstrated that arachidonic acid synergizes with p47phox phosphorylation in phagocytes to facilitate interaction with p22phox and to induce activation of phagocyte-NADPH oxidase.11 Consistent with these findings, platelet O2 production by arachidonic acid was almost completely suppressed in 2 patients with an inherited gp91phox deficiency.
Consistent with previous findings,12 aspirin did not affect platelet CD40L expression; in addition, aspirin marginally influenced platelet O2 expression, suggesting that NADPH oxidase activation mainly occurs through a COX1-independent mechanism. Several lines of evidence suggest that the CD40L-CD40 dyad is implicated in atherothrombosis. Engagement of CD40L with its receptor stimulates the synthesis of adhesion molecules, chemokines, and tissue factor and activates metalloproteinases.1,2 The role of CD40L in atherogenesis is confirmed by the fact that, in hyperlipidemic mice, anti-CD40L antibodies reduced the atherosclerotic lesion.13 Oxidized LDL seems to play a key role in pathogenesis of atherosclerosis; in a recent study,14 oxidized LDL dose dependently increased CD40L in human vascular endothelial cells and smooth muscle cells, suggesting that oxidative stress is implicated in CD40L expression. The fact that oxidative stress also plays a role in platelet CD40L expression suggests that an increase in CD40L expression might be another mechanism through which oxidative stress elicits the atherosclerotic damage.
In conclusion, this study demonstrates that platelet CD40L expression occurs via arachidonic acidmediated NADPH oxidase activation and suggests that scavenging O2 or reducing platelet release of arachidonic acid could represent a novel approach to inhibit CD40L expression.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. Pignatelli, R. Cangemi, A. Celestini, R. Carnevale, L. Polimeni, A. Martini, D. Ferro, L. Loffredo, and F. Violi Tumour necrosis factor {alpha} upregulates platelet CD40L in patients with heart failure Cardiovasc Res, June 1, 2008; 78(3): 515 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Li, J. M. Sanders, M. H. Bevard, Z. Sun, J. W. Chumley, E. V. Galkina, K. Ley, and I. J. Sarembock CD40 Ligand Promotes Mac-1 Expression, Leukocyte Recruitment, and Neointima Formation after Vascular Injury Am. J. Pathol., April 1, 2008; 172(4): 1141 - 1152. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Freedman Oxidative Stress and Platelets Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s11 - s16. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Cangemi, L. Loffredo, R. Carnevale, L. Perri, M. P. Patrizi, V. Sanguigni, P. Pignatelli, and F. Violi Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E Eur. Heart J., January 1, 2008; 29(1): 54 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Davi and C. Patrono Platelet Activation and Atherothrombosis N. Engl. J. Med., December 13, 2007; 357(24): 2482 - 2494. [Full Text] [PDF] |
||||
![]() |
F. Martino, P. Pignatelli, E. Martino, F. Morrone, R. Carnevale, S. Di Santo, B. Buchetti, L. Loffredo, and F. Violi Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1974 - 1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. von Hundelshausen and C. Weber Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease Circ. Res., January 5, 2007; 100(1): 27 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Alessandri, P. Pignatelli, L. Loffredo, L. Lenti, M. Del Ben, R. Carnevale, A. Perrone, D. Ferro, F. Angelico, and F. Violi Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2577 - 2578. [Full Text] [PDF] |
||||
![]() |
P. Pignatelli, S. Di Santo, B. Buchetti, V. Sanguigni, A. Brunelli, and F. Violi Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment FASEB J, June 1, 2006; 20(8): 1082 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pignatelli, V. Sanguigni, B. Buchetti, L. Lenti, F. Violi, A. Undas, and K. G. Mann Early Anticoagulant Effect of Atorvastatin Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): e145 - e146. [Full Text] [PDF] |
||||
![]() |
S. Chakrabarti, O. Vitseva, D. Iyu, S. Varghese, and J. E. Freedman The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 494 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chakrabarti, S. Varghese, O. Vitseva, K. Tanriverdi, and J. E. Freedman CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2428 - 2434. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Begonja, S. Gambaryan, J. Geiger, B. Aktas, M. Pozgajova, B. Nieswandt, and U. Walter Platelet NAD(P)H-oxidase-generated ROS production regulates {alpha}IIb{beta}3-integrin activation independent of the NO/cGMP pathway Blood, October 15, 2005; 106(8): 2757 - 2760. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |